DITRAP in the spotlight: RemAb Therapeutics secures 185 media appearances

From national newspapers to specialised healthcare publications, DITRAP partner RemAb Therapeutics has brought the project’s innovative research into the public spotlight, generating 185 media mentions and reaching a reported cumulative audience of more than 10.8 million.

The extensive media outreach campaign led by RemAb Therapeutics has significantly strengthened DITRAP’s visibility across Spain, raising awareness of its research and the consortium’s efforts to develop new strategies to prevent serious bacterial infections.

From scientific innovation to national headlines

The media coverage has highlighted RemAb’s innovative HART technology and the development of RA0127, a novel therapeutic candidate being investigated within DITRAP to help prevent Gram-negative bacterial infections in intensive care units (ICUs).

The campaign attracted attention from some of Spain’s most prominent media outlets, including La Vanguardia, El Confidencial, The Objective and El Economista. Coverage also extended to specialised healthcare publications, such as Vademecum and IM Médico Hospitalario, as well as regional and local media.

By reaching general, economic and healthcare audiences, the campaign has brought greater attention to RA0127’s proposed mechanism of action, which aims to selectively remove antibodies that interfere with the immune system’s ability to fight infections. It has also highlighted the European support behind DITRAP and the potential of collaborative research to address antimicrobial resistance.

Raising the profile of the DITRAP consortium

Beyond showcasing RemAb’s technology, this media outreach represents an important contribution to DITRAP’s communication and dissemination efforts, helping to raise awareness of the project’s scientific objectives and strengthen recognition of the consortium’s collective work.

The widespread coverage reinforces DITRAP’s presence in discussions on antimicrobial resistance and innovative therapeutic approaches, demonstrating how proactive communication can bring European-funded research closer to society.

Congratulations to RemAb Therapeutics for this successful outreach campaign and its contribution to making DITRAP and its research more widely known!